Tag: XpressCF+
Antibody-drug Conjugates: Coming of Age
Antibody-based anti-cancer therapeutics have, over the last 30+ years garnered considerable success. Antibody-drug Conjugates (ADC) are included in this revolution of these novel, highly...
Sutro Biopharma Receives Milestone Payment for Bispecific Antibody-Drug Conjugate from Merck
South San Francisco-based clinical-stage biotechnology company Sutro Biopharma has received a milestone payment under its collaboration and license agreement with the healthcare division of...
First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients...
A first patient has been dosed in the dose-expansion cohort of the Phase I study with STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug...
Annual World ADC – Best New Drug Developer 2020: Sutro Biopharma’s...
From liquid biopsies to precision medicine to immunology, the field of cancer treatment has experienced significant progress during the last decade. Although according to...
Preclinical Data Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors, Resulting...
Data presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020 of Sutro Biopharma's folate receptor...
SutroVax Closes U.S. $ 110 million Series D financing to Advance...
SutroVax, a next-generation vaccine company, has closed a $110 million Series D preferred stock financing, co-led by new investors RA Capital Management and Janus...
Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002...
Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented at the AACR-NCI-EORTC.
FRα is overexpressed...
Sutro Biopharma to Receive Milestone Payment from Merck KGaA for Bispecific...
Sutro Biopharma has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, in the United...
Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...
Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...
A New Generation of Precisely Engineered CD74-Targeting ADCs Receive Orphan Drug...
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for STRO-001 for the treatment of multiple myeloma (MM).
In the United States,...
